Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00534378 · ClinicalTrials.gov registry record · Phase 1

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

A Phase 1 study of Seizures, sponsored by U.S. Army Office of the Surgeon General.

Completed
Registry status
Phase 1
Development phase
39
Enrollment target
1
Study location

NCT00534378 is a Phase 1 study of Seizures that has completed, run by U.S. Army Office of the Surgeon General. The registered enrollment target is 39 participants, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00534378, a Phase 1 study of Seizures, has completed, sponsored by U.S. Army Office of the Surgeon General.

COMPLETED
Registry status
Phase 1
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

Purpose of the study is to determine midazolam's safety and dose-linearity when delivered intramuscularly via an autoinjector. The proposed initial treatment dosage for seizures induced by exposure to nerve agents.

Conditions Studied

Interventions

  • DRUG Midazolam

Study Locations (1)

Maryland

  • BASi Baltimore Clinical Research Unit - Baltimore

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2006-07
Est. Completion 2006-12
Phase Phase 1

What the Registry Record Tells You About NCT00534378

The ClinicalTrials.gov registry entry for NCT00534378 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (96% lower). The listed sponsor is U.S. Army Office of the Surgeon General, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Seizures appearing as the primary indexed condition, and to 1 intervention - of which Midazolam is the first listed.

NCT00534378 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00534378 about?

NCT00534378 is a clinical study titled "Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector". Purpose of the study is to determine midazolam's safety and dose-linearity when delivered intramuscularly via an autoinjector. The proposed initial treatment dosage for seizures induced by exposure to nerve agents.

What is the current status of trial NCT00534378?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2006-07. Estimated completion is 2006-12.

What conditions does trial NCT00534378 study?

This clinical trial studies the following conditions: Seizures.

What interventions are being tested in trial NCT00534378?

The interventions under investigation include: Midazolam (DRUG).

Who is sponsoring clinical trial NCT00534378?

This trial is sponsored by U.S. Army Office of the Surgeon General, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00534378 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seizures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.